Pharmacological and Combined Interventions for the Acute Depressive Episode: Focus on Efficacy and Tolerability

DSpace/Manakin Repository

Pharmacological and Combined Interventions for the Acute Depressive Episode: Focus on Efficacy and Tolerability

Citable link to this page

. . . . . .

Title: Pharmacological and Combined Interventions for the Acute Depressive Episode: Focus on Efficacy and Tolerability
Author: Brunoni, Andre R; Fraguas, Renerio; Fregni, Felipe

Note: Order does not necessarily reflect citation order of authors.

Citation: Brunoni, Andre R., Renerio Fraguas, and Felipe Fregni. 2009. Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability. Therapeutics and Clinical Risk Management 5: 897-910.
Full Text & Related Files:
Abstract: Background: Use of antidepressants is the gold standard therapy for major depression. However, despite the large number of commercially available antidepressant drugs there are several differences among them in efficacy, tolerability, and cost-effectiveness. In addition the optimal augmentation strategy is still not clear when dealing with treatment-resistant depression, a condition that affects 15% to 40% of depressed patients. Methods: We therefore reviewed the main characteristics of these drugs regarding their efficacy, tolerability, side effects and cost-effectiveness, by accessing all meta-analyses and systematic reviews published from 2004 to 2009. In addition, we reviewed the augmentation strategy of associated antidepressants with neurostimulation therapies (such as transcranial magnetic stimulation [TMS] and transcranial direct current stimulation [tDCS]). A search was undertaken in MEDLINE, Web of Science, Cochrane, and Scielo databases. We included: 21 meta-analyses of antidepressant trials, 15 neurostimulation clinical trials and 8 studies of pharmacoeconomics. We then performed a comprehensive review on these articles. Results and Conclusion: Although recent meta-analyses suggest sertraline and escitalopram might have increased efficacy/tolerability, other studies and large pragmatic trials have not found these to be superior to other antidepressant drugs. Also, we did not identify any superior drug in terms of cost-effectiveness due to the different designs observed among pharmacoecomics studies. Side effects such as sexual dysfunction, gastrointestinal problems and weight gain were common causes of discontinuation. Tolerability was an important issue for novel neurostimulation interventions, such as TMS and tDCS. These therapies might be interesting augmentation strategies, considering their benign profile of side effects, if proper safety parameters are adopted.
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781064/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4745728

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters